IBDEI0PH ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12493,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12493,1,1,0)
 ;;=1^V79.1
 ;;^UTILITY(U,$J,358.3,12493,1,8,0)
 ;;=8^Alcoholism Screening
 ;;^UTILITY(U,$J,358.3,12493,2)
 ;;=^295678
 ;;^UTILITY(U,$J,358.3,12494,0)
 ;;=V79.0^^70^764^3
 ;;^UTILITY(U,$J,358.3,12494,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12494,1,1,0)
 ;;=1^V79.0
 ;;^UTILITY(U,$J,358.3,12494,1,8,0)
 ;;=8^Depression Screening
 ;;^UTILITY(U,$J,358.3,12494,2)
 ;;=^295677
 ;;^UTILITY(U,$J,358.3,12495,0)
 ;;=V65.49^^70^764^7
 ;;^UTILITY(U,$J,358.3,12495,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12495,1,1,0)
 ;;=1^V65.49
 ;;^UTILITY(U,$J,358.3,12495,1,8,0)
 ;;=8^Medication Counseling
 ;;^UTILITY(U,$J,358.3,12495,2)
 ;;=^303471
 ;;^UTILITY(U,$J,358.3,12496,0)
 ;;=V66.2^^70^764^2
 ;;^UTILITY(U,$J,358.3,12496,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12496,1,1,0)
 ;;=1^V66.2
 ;;^UTILITY(U,$J,358.3,12496,1,8,0)
 ;;=8^Chemotherapy Convalescen
 ;;^UTILITY(U,$J,358.3,12496,2)
 ;;=^295568
 ;;^UTILITY(U,$J,358.3,12497,0)
 ;;=V76.10^^70^764^8
 ;;^UTILITY(U,$J,358.3,12497,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12497,1,1,0)
 ;;=1^V76.10
 ;;^UTILITY(U,$J,358.3,12497,1,8,0)
 ;;=8^Screen Mal Neop-Breast,Unsp
 ;;^UTILITY(U,$J,358.3,12497,2)
 ;;=^317968
 ;;^UTILITY(U,$J,358.3,12498,0)
 ;;=V76.2^^70^764^9
 ;;^UTILITY(U,$J,358.3,12498,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12498,1,1,0)
 ;;=1^V76.2
 ;;^UTILITY(U,$J,358.3,12498,1,8,0)
 ;;=8^Screen Mal Neop-Cervix
 ;;^UTILITY(U,$J,358.3,12498,2)
 ;;=^295653
 ;;^UTILITY(U,$J,358.3,12499,0)
 ;;=V76.41^^70^764^10
 ;;^UTILITY(U,$J,358.3,12499,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12499,1,1,0)
 ;;=1^V76.41
 ;;^UTILITY(U,$J,358.3,12499,1,8,0)
 ;;=8^Screen Mal Neop-Rectum
 ;;^UTILITY(U,$J,358.3,12499,2)
 ;;=^295655
 ;;^UTILITY(U,$J,358.3,12500,0)
 ;;=V26.33^^70^764^6
 ;;^UTILITY(U,$J,358.3,12500,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12500,1,1,0)
 ;;=1^V26.33
 ;;^UTILITY(U,$J,358.3,12500,1,8,0)
 ;;=8^Genetic Counseling
 ;;^UTILITY(U,$J,358.3,12500,2)
 ;;=^332865
 ;;^UTILITY(U,$J,358.3,12501,0)
 ;;=V58.11^^70^764^5
 ;;^UTILITY(U,$J,358.3,12501,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12501,1,1,0)
 ;;=1^V58.11
 ;;^UTILITY(U,$J,358.3,12501,1,8,0)
 ;;=8^Encounter for Chemotherapy
 ;;^UTILITY(U,$J,358.3,12501,2)
 ;;=^332869
 ;;^UTILITY(U,$J,358.3,12502,0)
 ;;=V58.83^^70^764^11
 ;;^UTILITY(U,$J,358.3,12502,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12502,1,1,0)
 ;;=1^V58.83
 ;;^UTILITY(U,$J,358.3,12502,1,8,0)
 ;;=8^Therapeutic Drug Monitoring
 ;;^UTILITY(U,$J,358.3,12502,2)
 ;;=^322076
 ;;^UTILITY(U,$J,358.3,12503,0)
 ;;=282.60^^70^765^6
 ;;^UTILITY(U,$J,358.3,12503,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12503,1,1,0)
 ;;=1^282.60
 ;;^UTILITY(U,$J,358.3,12503,1,8,0)
 ;;=8^Sickle-Cell Anemia Nos
 ;;^UTILITY(U,$J,358.3,12503,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,12504,0)
 ;;=282.62^^70^765^3
 ;;^UTILITY(U,$J,358.3,12504,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12504,1,1,0)
 ;;=1^282.62
 ;;^UTILITY(U,$J,358.3,12504,1,8,0)
 ;;=8^Hb-S Disease With Crisis
 ;;^UTILITY(U,$J,358.3,12504,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,12505,0)
 ;;=282.61^^70^765^2
 ;;^UTILITY(U,$J,358.3,12505,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12505,1,1,0)
 ;;=1^282.61
 ;;^UTILITY(U,$J,358.3,12505,1,8,0)
 ;;=8^Hb-S Disease W/O Crisis
 ;;^UTILITY(U,$J,358.3,12505,2)
 ;;=^267981
 ;;^UTILITY(U,$J,358.3,12506,0)
 ;;=282.69^^70^765^5
 ;;^UTILITY(U,$J,358.3,12506,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12506,1,1,0)
 ;;=1^282.69
 ;;^UTILITY(U,$J,358.3,12506,1,8,0)
 ;;=8^Other Sickle Cell Dis w/ Crisis
